+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

AI-enabled Wound Analysis - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • PDF Icon

    Report

  • 180 Pages
  • July 2026
  • Region: Global
  • Mordor Intelligence
  • ID: 6261002
The aI-enabled wound analysis market size was valued at USD 1.58 billion in 2025 and is estimated to grow from USD 1.81 billion in 2026 to reach USD 3.62 billion by 2031, at a CAGR of 14.85% during the forecast period (2026-2031). This report is Segmented by Product Type (smartphone Based Applications, Software, and More), Application (Wound Assessment and Monitoring, Healing Prediction and Decision Support, and More), Wound Type (Chronic Wounds, Acute Wounds, and More), End User (Hospitals, Home Healthcare Agencies, and More), and Geography (North America, Europe, and More). Market Forecasts are Provided in Terms of Value (USD).

Global AI-enabled Wound Analysis Market Trends and Insights

Rising Chronic Wound Burden and Diabetic Ulcer Surveillance Needs

Chronic wound prevalence is creating a surveillance need that manual assessment cannot meet at scale. Globally, approximately 18.6 million people worldwide develop diabetic foot ulcers each year, and these ulcers precede 80% of lower-limb amputations among people diagnosed with diabetes.Southeast Asia alone had more than 107 million people with diabetes in 2025, a figure projected to reach 185 million by 2050. Diabetic foot ulcer recurrence can reach 65% within 3 to 5 years after initial healing, which shifts the value of AI wound analysis from one-time support to ongoing surveillance infrastructure. In Europe, chronic wounds had a prevalence of 2.2 per 1,000 people, and diabetic foot disease is estimated to affect 16 million people over their lifetime across the WHO European Region, which supports the case for image-based monitoring at scale.

Hospital Workflow Pressure and Demand for Faster Bedside Assessment

Wound care takes a heavy share of nursing time in inpatient settings, and burnout is making the capacity problem more severe. A Net Health Q1 2025 survey found that 77.00% of wound care professionals reported significant burnout, while 47% identified smart documentation tools as a critical relief mechanism. AI-enabled bedside imaging reduces measurement variability, removes ruler-based errors, and lets non-specialist staff capture clinically valid documentation during routine care. A 2025 study published in PMC found that a digitally enabled wound care system used across 14 home health branches reduced skilled nursing visits per episode and created potential annual savings of up to USD 958,201 across a single home health organization. This cost-avoidance logic helps explain why hospitals in the AI-enabled wound analysis market are adopting documentation and surveillance tools even when formal evidence development is still catching up with operational demand.

Clinical Validation Gaps Across Diverse Skin Tones and Wound Presentations

AI wound analysis tools still face a measurable equity gap that creates clinical and procurement risk for health systems. A 2025 PLOS One study evaluating a surgical wound AI system reported 89% overall sensitivity, but it also found lower detection accuracy for some wound features in darker skin tones. An IEEE BHI study in 2025 described datasets designed for diabetic foot ulcer recognition in communities of color because many existing models have been trained mainly on lighter-skinned populations. Published work in npj Digital Medicine has also reinforced the wider issue of skin-tone assessment and performance reporting in medical AI, which increases pressure on vendors to show more inclusive validation. A 2025 review in the Chinese Journal of Injury Repair and Wound Care likewise identified data diversity as a central unresolved challenge for AI use in chronic wound management.

Other drivers and restraints analyzed in the detailed report include:

  • Standardized Documentation and Reimbursement Traceability Requirements
  • Expansion of Remote Wound Monitoring and Telewound Programs
  • Integration Friction with Legacy EHR and Nonstandard Imaging Workflows

Segment Analysis

Smartphone applications held 36.18% of the AI-enabled wound analysis market size in 2025, which made them the largest product segment because the imaging hardware was already in the hands of bedside and community clinicians. Telemedicine platforms are projected to expand at an 18.81% CAGR through 2031 as health systems continue to invest in asynchronous wound review models that shift specialist time away from routine documentation. This product split reflects a practical buying pattern in which providers first choose the lowest-friction capture tool and then add review workflows around it. EMR integration software remains less visible in revenue terms, but it has a structurally important role because it determines whether wound images and measurements change the clinical workflow or stay trapped in a standalone app. AI-enabled imaging hardware occupies the high-precision tier, especially in spectral, fluorescence, and near-infrared formats, where buyers are looking for deeper tissue and infection-related signals.

The imaging hardware tier is moving forward through regulatory validation and tighter pairing with software platforms. Swift Medical's FDA 510 (k)-cleared Swift Ray 1, announced in March 2026, showed this direction by linking handheld spectral imaging with a broader AI wound platform intended for hospital, home health, and remote care use. Product competition in the AI-enabled wound analysis market is therefore separating into mobile-first tools built for scale and device-led platforms built for depth. Smartphone-based applications remain easiest to deploy where budgets and training time are limited. Hardware-led platforms hold stronger positions in settings that want regulatory credentials and richer wound data at the point of care.

Wound assessment and monitoring held 41.68% share in 2025 because standardized measurement remains the first and most common use case across the AI-enabled wound analysis market. Healing prediction and decision support is projected to grow at a 17.86% CAGR through 2031 as providers start to use AI not only to describe the wound but also to guide treatment and follow-up. This changes the commercial discussion from documentation quality alone to expected healing outcomes and better use of staff time. Infection detection and tissue characterization remain clinically important, but adoption is slower because these workflows often rely on more advanced devices and extra training. Remote wound documentation and care coordination are also expanding because image capture has become more central to how providers manage wounds across care settings.

The application mix shows that buyers usually start with measurement and then move toward prediction. MolecuLightDX received FDA qualification as a Medical Device Development Tool in January 2026, which strengthened the clinical standing of fluorescence-based wound measurement in research and product evaluation. As telemedicine investment continues, remote documentation is becoming harder to separate from broader care coordination. This means the AI-enabled wound analysis industry is moving toward applications that combine measurement, review, and longitudinal planning rather than isolated imaging functions alone.

Complete Report Scope:

  • By Product Type
    • Smartphone Based Applications
    • Telemedicine Platforms
    • Electronic Medical Record Integration Software
    • AI Enabled Imaging Hardware
  • By Application
    • Wound Assessment and Monitoring
    • Healing Prediction and Decision Support
    • Infection Detection and Tissue Characterization
    • Remote Wound Documentation and Care Coordination
  • By Wound Type
    • Chronic Wounds
    • Acute Wounds
    • Surgical Wounds
    • Burn Wounds
  • By End User
    • Hospitals
    • Home Healthcare Agencies
    • Specialty Clinics
    • Long Term Care Facilities
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • India
      • Japan
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • South America
      • Brazil
      • Argentina
      • Rest of South America

Geography Analysis

North America held 41.87% of AI-enabled wound analysis market share in 2025, which made it the largest regional segment. The region benefits from stronger regulatory infrastructure, deeper specialist presence, and greater payer focus on documentation standards. Canada also acts as an active development hub, reflected in Swift Medical's 2026 FDA 510 (k) clearance and federal co-investment through the DIGITAL Supercluster program. Mexico remains earlier in adoption because healthcare IT gaps still limit near-term rollout. This makes North America the reference region for product design, validation expectations, and procurement timing across the broader AI-enabled wound analysis market.

Europe is advancing through a more evidence-first adoption path, and the United Kingdom stands out as the most mature deployment setting in the region. Germany and France are progressing within the EU MDR framework, which favors vendors that can support stronger post-market evidence and compliance discipline. eKare's April 2025 partnership with Oxford Health NHS Foundation Trust reflects the European preference for proving clinical and economic value before scaling procurement.

Asia-Pacific is projected to expand at a 19.34% CAGR from 2026 to 2031, which makes it the fastest-growing region in the AI-enabled wound analysis market size by geography. India's digital health buildout, China's AI device review momentum, and Japan's publicly funded wound AI work are supporting that pace. A 2025 Chinese review identified wound assessment, remote monitoring, and decision support as the main clinical deployment areas for AI in chronic wound management.



List of Companies Covered in this Report:

  • ARANZ Medical
  • BioVisual Technologies LLC
  • ConvaTec Group plc
  • eKare, Inc.
  • Healthy.io Ltd.
  • Intellicure, Inc.
  • Joerns Healthcare
  • Kent Imaging
  • MolecuLight
  • NATROX Wound Care
  • Net Health Systems, Inc.
  • Perceptive Solutions, Inc.
  • Smiths Group
  • Solventum Corporation
  • Swift Medical Inc.
  • Tissue Health Plus
  • WoundMatrix, Inc.
  • WoundRight Technologies, LLC
  • WoundVision, LLC
  • WoundZoom, Inc.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY3 EXECUTIVE SUMMARY
4 MARKET LANDSCAPE
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Chronic Wound Burden and Diabetic Ulcer Surveillance Needs
4.2.2 Hospital Workflow Pressure and Demand for Faster Bedside Assessment
4.2.3 Standardized Documentation and Reimbursement Traceability Requirements
4.2.4 Expansion of Remote Wound Monitoring and Telewound Programs
4.2.5 AI-Assisted Infection Detection From Multimodal Imaging at Point of Care
4.2.6 Cross-Device Interoperability With EHR and Care Coordination Platforms
4.3 Market Restraints
4.3.1 Clinical Validation Gaps Across Diverse Skin Tones and Wound Presentations
4.3.2 Integration Friction With Legacy EHR and Nonstandard Imaging Workflows
4.3.3 Reimbursement Uncertainty for AI-Enabled Wound Assessment in Some Care Settings
4.3.4 Data Governance Constraints for Image Storage, Consent, and Cross-Site Analytics
4.4 Value Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Suppliers
4.7.3 Bargaining Power of Buyers
4.7.4 Threat of Substitutes
4.7.5 Competitive Rivalry
5 MARKET SIZE AND GROWTH FORECASTS (VALUE, USD)
5.1 By Product Type
5.1.1 Smartphone Based Applications
5.1.2 Telemedicine Platforms
5.1.3 Electronic Medical Record Integration Software
5.1.4 AI Enabled Imaging Hardware
5.2 By Application
5.2.1 Wound Assessment and Monitoring
5.2.2 Healing Prediction and Decision Support
5.2.3 Infection Detection and Tissue Characterization
5.2.4 Remote Wound Documentation and Care Coordination
5.3 By Wound Type
5.3.1 Chronic Wounds
5.3.2 Acute Wounds
5.3.3 Surgical Wounds
5.3.4 Burn Wounds
5.4 By End User
5.4.1 Hospitals
5.4.2 Home Healthcare Agencies
5.4.3 Specialty Clinics
5.4.4 Long Term Care Facilities
5.5 By Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 India
5.5.3.3 Japan
5.5.3.4 South Korea
5.5.3.5 Australia
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East and Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
6.3.1 ARANZ Medical Limited
6.3.2 BioVisual Technologies LLC
6.3.3 ConvaTec Group plc
6.3.4 eKare, Inc.
6.3.5 Healthy.io Ltd.
6.3.6 Intellicure, Inc.
6.3.7 Joerns Healthcare LLC
6.3.8 Kent Imaging Inc.
6.3.9 MolecuLight Inc.
6.3.10 NATROX Wound Care
6.3.11 Net Health Systems, Inc.
6.3.12 Perceptive Solutions, Inc.
6.3.13 Smith and Nephew plc
6.3.14 Solventum Corporation
6.3.15 Swift Medical Inc.
6.3.16 Tissue Health Plus
6.3.17 WoundMatrix, Inc.
6.3.18 WoundRight Technologies, LLC
6.3.19 WoundVision, LLC
6.3.20 WoundZoom, Inc.
7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK
7.1 White Space and Unmet Need Assessment

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • ARANZ Medical Limited
  • BioVisual Technologies LLC
  • ConvaTec Group plc
  • eKare, Inc.
  • Healthy.io Ltd.
  • Intellicure, Inc.
  • Joerns Healthcare LLC
  • Kent Imaging Inc.
  • MolecuLight Inc.
  • NATROX Wound Care
  • Net Health Systems, Inc.
  • Perceptive Solutions, Inc.
  • Smith and Nephew plc
  • Solventum Corporation
  • Swift Medical Inc.
  • Tissue Health Plus
  • WoundMatrix, Inc.
  • WoundRight Technologies, LLC
  • WoundVision, LLC
  • WoundZoom, Inc.